21:35 , Sep 29, 2017 |  BC Week In Review  |  Clinical News

Genocea discontinues HSV-2 candidate GEN-003

Genocea Biosciences Inc. (NASDAQ:GNCA) said it is "exploring strategic alternatives" and ceasing development of GEN-003, which has completed Phase II testing to treat genital herpes simplex virus type 2 (HSV-2) infection. The company will reduce...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

GEN-003: Phase IIb data

Top-line data from a double-blind, U.S. Phase IIb trial in 131 patients with genital HSV-2 infection showed that 60 ug intramuscular GEN-003 containing 50 ug Matrix M given 3 times 21 days apart met the...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Clinical News

GEN-003: Additional Phase II data

Additional data from a double-blind, placebo-controlled, U.S. Phase II trial in 310 patients with chronic genital HSV-2 infection showed that 60 ug intramuscular GEN-003 containing 50 or 75 ug Matrix M given 3 times 21...
01:23 , Apr 1, 2016 |  BC Extra  |  Clinical News

Genocea gains on 12-month HSV data

Genocea Biosciences Inc. (NASDAQ:GNCA) gained $3.77 (95%) to $7.74 on Thursday after reporting 12-month data from a Phase II trial of herpes simplex virus-2 (HSV-2) candidate GEN-003 . The company believes a three-injection course of...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Clinical News

GEN-003: Phase IIb started

Genocea began a placebo-controlled, U.S. Phase IIb trial to evaluate 2 dose levels of GEN-003 given as 3 injections 21 days apart in about 135 patients. Genocea has rights from Novavax to use the Matrix...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

GEN-003: Additional Phase II data

Additional data from a double-blind, placebo-controlled, U.S. Phase II trial in 310 patients with chronic genital HSV-2 infection showed that 60 ug intramuscular GEN-003 containing 75 ug Matrix M given 3 times 21 days apart...
01:37 , Oct 8, 2015 |  BC Extra  |  Clinical News

Genocea rises on six-month HSV-2 data

Genocea Biosciences Inc. (NASDAQ:GNCA) gained $0.49 to $6.39 after it said GEN-003 significantly reduced viral shedding in an interim analysis of a Phase II trial to treat herpes simplex virus-2 (HSV-2), meeting the study's primary...
03:44 , Jul 31, 2015 |  BC Extra  |  Financial News

Genocea raises $50.1M in follow-on

Genocea Biosciences Inc. (NASDAQ:GNCA) raised $50.1 million through the sale of 3.9 million shares at $13 in a follow-on underwritten by Cowen; Piper Jaffray; Stifel; and Needham. Genocea proposed the offering after market close Wednesday;...
07:00 , May 25, 2015 |  BC Week In Review  |  Clinical News

GEN-003: Phase II data

Top-line data from a double-blind, placebo-controlled, U.S. Phase II trial in 310 patients with chronic genital HSV-2 infection showed that 30 and 60 ug intramuscular GEN-003 containing 25, 50 or 75 ug Matrix M given...
01:56 , May 21, 2015 |  BC Extra  |  Clinical News

Genocea rises on Phase II HSV data

Genocea Biosciences Inc. (NASDAQ:GNCA) gained $0.94 to $11.59 on Tuesday after it said all six dosing combinations that included lead candidate GEN-003 met the primary endpoint in a Phase II dose optimization trial to treat...